Treinamento físico melhora a disfunção quimiorreflexa em ratos diabéticos por estreptozotocina

The aim of the present study was to investigate the effects of exercise training on arterial pressure, heart rate and chemoreflex sensitivity in STZ-induced diabetic rats. The animals were divided into three groups: control (SC, n = 6), sedentary diabetic (SD, n = 6) and trained diabetic (TD, n = 6). After 1 week of diabetes induction (Streptozotocin, 50 mg/kg, iv), male Wistar rats were submitted to exercise training for 10 weeks on a treadmill. Arterial pressure signals were obtained and processed with a data acquisition system (CODAS, 1 KHz). Potassium cyanide (KCN, 100ug/kg) was used to evaluated bradycardic response evoked by chemoreflex activation. Diabetes bradycardia and hypotension (SD: 274 ± 6 bpm and 94 ± 2 mmHg vs SC: 332 ± 5bpm and 108 ± 2 mmHg) were attenuated by training (TD: 299 ± 5 bpm and 107 ± 2 mmHg). Bradycardic response was decreased in SD rats (33 ± 5 bpm) when compared to SC rats (182 ± 3 bpm) and TD rats (89 ± 10 bpm). In conclusion, exercise training reversed hypotension and bradycardia and improved chemreflex sensitivity in STZ-diabetic rats. Considering that diabetics with abnormal cardiovascular reflexes show higher mortality than diabetics with normal autonomic reflex function, the results obtained suggest that exercise training may contribute to the reduction in cardiovascular risk in this population and must be considered in the management of diabetic patientsO objetivo do presente estudo foi avaliar os efeitos do treinamento físico na pressão arterial, na freq üência cardíaca e na sensibilidade quimiorreflexa em ratos diabéticos por estreptozotocina. Os animais foram divididos em grupos controle (CS, n = 6), diabético sedentário (DS, n = 6) e diabético treinado (DT, n = 6). Uma semana após a indução do diabetes (Estreptozotocina, 50 mg/kg), ratos machos Wistar foram submetidos a um protocolo de treinamento físico em esteira ergométrica por 10 semanas. Os sinais de pressão arterial foram gravados e processados em um sistema de aquisição de dados (CODAS,1KHz). Cianeto de potássio (KCN,100 ug/kg) foi utilizado para avaliar a resposta bradicárdica desencadeada pela estimulação dos quimiorreceptores. A bradicardia e a hipotensão do diabetes (DS:274 ± 6 bpm e 94 ± 2 mmHg vs CS:332 ± 5 bpm e 108 ± 2 mmHg) foram atenuadas pelo treinamento físico (DT:299 ± 5 bpm e 107 ± 2 mmHg). A resposta bradicárdica foi menor nos ratos DS (33 ± 5 bpm) quando comparado aos ratos CS (182 ± 3 bpm) e DT (89 ± 10 bpm). Concluindo, o treinamento físico reverteu a hipotensão e a bradicardia e melhorou a sensibilidade quimioreflexa em ratos STZ. Considerando que diabéticos com reflexos cardiovasculares anormais apresentam maior mortalidade que diabéticos com função reflexa autonômica normal, os resultados obtidos sugerem que o treinamento físico pode contribuir para a redução do risco cardiovascular nesta população devendo ser considerado no manejo do paciente diabétic

In vitro experiments and infrared spectroscopy analysis of acid and alkaline phosphatase inhibition by vanadium complexes

In the course of our research of vanadium-containing complexes, two oxidovanadium complexes containing vanadium(V) and (IV) core with 4-aminobenzoic acid and/or peroxo anion as ligands were synthesized and characterized by elemental analysis, conductivity measurements, thermogravimetric analysis, and spectroscopies.(([VO(O 2 )(C 7 H 6 NO 2 )(H 2 O)] . H 2 O, [VO(C 7 H 6 NO 2 ) 2 H 2 O]) were supported by experimental data and theoretical studies (Density functional theory, DFT). The complexes were evaluated in vitro as phosphatase inhibitors (alkaline and acid enzymes) being considered as potential pharmaceutical agents under over-expression of those biochemical markers.The effect achieved was then analysed through FTIR spectroscopy. Changes in the finger print substrate bands as well as induced conformational changes on phosphatases enzymes secondary structure were further examined. Eventually albumin interactions experimentswere performed in order to derive their bioavailability.Fil: Parente, Juliana Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Química Inorgánica "Dr. Pedro J. Aymonino". Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Química Inorgánica "Dr. Pedro J. Aymonino"; ArgentinaFil: Naso, Luciana Gissella. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Química Inorgánica "Dr. Pedro J. Aymonino". Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Química Inorgánica "Dr. Pedro J. Aymonino"; ArgentinaFil: Jori, Khalil. Universidad Nacional de La Plata; ArgentinaFil: Franca, Carlos Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Química Inorgánica "Dr. Pedro J. Aymonino". Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Química Inorgánica "Dr. Pedro J. Aymonino"; ArgentinaFil: da Costa Ferreira, Ana Maria. Universidade de Sao Paulo; BrasilFil: Williams, Patricia Ana María. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Química Inorgánica "Dr. Pedro J. Aymonino". Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Química Inorgánica "Dr. Pedro J. Aymonino"; ArgentinaFil: Ferrer, Evelina Gloria. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Química Inorgánica "Dr. Pedro J. Aymonino". Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Química Inorgánica "Dr. Pedro J. Aymonino"; Argentin

In vitro experiments and infrared spectroscopy analysis of acid and alkaline phosphatase inhibition by vanadium complexes

In the course of our research on vanadium-containing complexes, two oxidovanadium complexes containing vanadium(V) and (IV) cores with 4-aminobenzoic acid and/or the peroxo anion as ligands were synthesized and characterized by elemental analysis, conductivity measurements, thermogravimetric analysis, and 1H NMR, EPR, FTIR, and UV/vis spectroscopies. Their compositions and geometrical structures ([VO(O2)(C7H6NO2)(H2O)]·H2O and [VO(C7H6NO2)2H2O]) were supported by experimental data and theoretical studies (density functional theory, DFT). The complexes were evaluated in vitro as phosphatase inhibitors (alkaline and acid enzymes), being considered as potential pharmaceutical agents under over-expression of those biochemical markers. The effect achieved was then analysed through FTIR spectroscopy. Changes in the fingerprint substrate bands as well as induced conformational changes in phosphatase enzymes’ secondary structure were further examined. Eventually albumin interaction experiments were performed in order to derive their bioavailability.Centro de Química Inorgánic

Versatility in the biological behavior of two aminobenzoate oxidovanadium (V, IV) compounds. Inhibition or simulation of enzymes

The pharmacological potential of vanadium compounds is of great interest to researchers in treatments of various diseases (diabetes, cancer, tropical endemic diseases, etc.). On the basis of the potential biological/pharmacological applications, in this work we have synthesized and physico-chemically characterized, two new complexes containing vanadium (IV) and (V) with 4-aminobenzoic acid as the ligand (L)

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR)

Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings.Fil: Pons Estel, Bernardo A.. Centro Regional de Enfermedades Autoinmunes y Reumáticas; ArgentinaFil: Bonfa, Eloisa. Universidade de Sao Paulo; BrasilFil: Soriano, Enrique R.. Instituto Universitario Hospital Italiano de Buenos Aires. Rectorado.; ArgentinaFil: Cardiel, Mario H.. Centro de Investigación Clínica de Morelia; MéxicoFil: Izcovich, Ariel. Hospital Alemán; ArgentinaFil: Popoff, Federico. Hospital Aleman; ArgentinaFil: Criniti, Juan M.. Hospital Alemán; ArgentinaFil: Vásquez, Gloria. Universidad de Antioquia; ColombiaFil: Massardo, Loreto. Universidad San Sebastián; ChileFil: Duarte, Margarita. Hospital de Clínicas; ParaguayFil: Barile Fabris, Leonor A.. Hospital Angeles del Pedregal; MéxicoFil: García, Mercedes A.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Amigo, Mary Carmen. Centro Médico Abc; MéxicoFil: Espada, Graciela. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez"; ArgentinaFil: Catoggio, Luis J.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Sato, Emilia Inoue. Universidade Federal de Sao Paulo; BrasilFil: Levy, Roger A.. Universidade do Estado de Rio do Janeiro; BrasilFil: Acevedo Vásquez, Eduardo M.. Universidad Nacional Mayor de San Marcos; PerúFil: Chacón Díaz, Rosa. Policlínica Méndez Gimón; VenezuelaFil: Galarza Maldonado, Claudio M.. Corporación Médica Monte Sinaí; EcuadorFil: Iglesias Gamarra, Antonio J.. Universidad Nacional de Colombia; ColombiaFil: Molina, José Fernando. Centro Integral de Reumatología; ColombiaFil: Neira, Oscar. Universidad de Chile; ChileFil: Silva, Clóvis A.. Universidade de Sao Paulo; BrasilFil: Vargas Peña, Andrea. Hospital Pasteur Montevideo; UruguayFil: Gómez Puerta, José A.. Hospital Clinic Barcelona; EspañaFil: Scolnik, Marina. Instituto Universitario Hospital Italiano de Buenos Aires. Rectorado.; ArgentinaFil: Pons Estel, Guillermo J.. Centro Regional de Enfermedades Autoinmunes y Reumáticas; Argentina. Hospital Provincial de Rosario; ArgentinaFil: Ugolini Lopes, Michelle R.. Universidade de Sao Paulo; BrasilFil: Savio, Verónica. Instituto Universitario Hospital Italiano de Buenos Aires. Rectorado.; ArgentinaFil: Drenkard, Cristina. University of Emory; Estados UnidosFil: Alvarellos, Alejandro J.. Hospital Privado Universitario de Córdoba; ArgentinaFil: Ugarte Gil, Manuel F.. Universidad Cientifica del Sur; Perú. Hospital Nacional Guillermo Almenara Irigoyen; PerúFil: Babini, Alejandra. Instituto Universitario Hospital Italiano de Buenos Aires. Rectorado.; ArgentinaFil: Cavalcanti, André. Universidade Federal de Pernambuco; BrasilFil: Cardoso Linhares, Fernanda Athayde. Hospital Pasteur Montevideo; UruguayFil: Haye Salinas, Maria Jezabel. Hospital Privado Universitario de Córdoba; ArgentinaFil: Fuentes Silva, Yurilis J.. Universidad de Oriente - Núcleo Bolívar; VenezuelaFil: Montandon De Oliveira E Silva, Ana Carolina. Universidade Federal de Goiás; BrasilFil: Eraso Garnica, Ruth M.. Universidad de Antioquia; ColombiaFil: Herrera Uribe, Sebastián. Hospital General de Medellin Luz Castro de Gutiérrez; ColombiaFil: Gómez Martín, DIana. Instituto Nacional de la Nutrición Salvador Zubiran; MéxicoFil: Robaina Sevrini, Ricardo. Universidad de la República; UruguayFil: Quintana, Rosana M.. Hospital Provincial de Rosario; Argentina. Centro Regional de Enfermedades Autoinmunes y Reumáticas; ArgentinaFil: Gordon, Sergio. Hospital Interzonal General de Agudos Dr Oscar Alende. Unidad de Reumatología y Enfermedades Autoinmunes Sistémicas; ArgentinaFil: Fragoso Loyo, Hilda. Instituto Nacional de la Nutrición Salvador Zubiran; MéxicoFil: Rosario, Violeta. Hospital Docente Padre Billini; República DominicanaFil: Saurit, Verónica. Hospital Privado Universitario de Córdoba; ArgentinaFil: Appenzeller, Simone. Universidade Estadual de Campinas; BrasilFil: Dos Reis Neto, Edgard Torres. Universidade Federal de Sao Paulo; BrasilFil: Cieza, Jorge. Hospital Nacional Edgardo Rebagliati Martins; PerúFil: González Naranjo, Luis A.. Universidad de Antioquia; ColombiaFil: González Bello, Yelitza C.. Ceibac; MéxicoFil: Collado, María Victoria. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaFil: Sarano, Judith. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaFil: Retamozo, Maria Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Sattler, María E.. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Perón"; ArgentinaFil: Gamboa Cárdenas, Rocio V.. Hospital Nacional Guillermo Almenara Irigoyen; PerúFil: Cairoli, Ernesto. Universidad de la República; UruguayFil: Conti, Silvana M.. Hospital Provincial de Rosario; ArgentinaFil: Amezcua Guerra, Luis M.. Instituto Nacional de Cardiologia Ignacio Chavez; MéxicoFil: Silveira, Luis H.. Instituto Nacional de Cardiologia Ignacio Chavez; MéxicoFil: Borba, Eduardo F.. Universidade de Sao Paulo; BrasilFil: Pera, Mariana A.. Hospital Interzonal General de Agudos General San Martín; ArgentinaFil: Alba Moreyra, Paula B.. Universidad Nacional de Córdoba. Facultad de Medicina; ArgentinaFil: Arturi, Valeria. Hospital Interzonal General de Agudos General San Martín; ArgentinaFil: Berbotto, Guillermo A.. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Perón"; ArgentinaFil: Gerling, Cristian. Hospital Interzonal General de Agudos Dr Oscar Alende. Unidad de Reumatología y Enfermedades Autoinmunes Sistémicas; ArgentinaFil: Gobbi, Carla Andrea. Universidad Nacional de Córdoba. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Gervasoni, Viviana L.. Hospital Provincial de Rosario; ArgentinaFil: Scherbarth, Hugo R.. Hospital Interzonal General de Agudos Dr Oscar Alende. Unidad de Reumatología y Enfermedades Autoinmunes Sistémicas; ArgentinaFil: Brenol, João C. Tavares. Hospital de Clinicas de Porto Alegre; BrasilFil: Cavalcanti, Fernando. Universidade Federal de Pernambuco; BrasilFil: Costallat, Lilian T. Lavras. Universidade Estadual de Campinas; BrasilFil: Da Silva, Nilzio A.. Universidade Federal de Goiás; BrasilFil: Monticielo, Odirlei A.. Hospital de Clinicas de Porto Alegre; BrasilFil: Seguro, Luciana Parente Costa. Universidade de Sao Paulo; BrasilFil: Xavier, Ricardo M.. Hospital de Clinicas de Porto Alegre; BrasilFil: Llanos, Carolina. Universidad Católica de Chile; ChileFil: Montúfar Guardado, Rubén A.. Instituto Salvadoreño de la Seguridad Social; El SalvadorFil: Garcia De La Torre, Ignacio. Hospital General de Occidente; MéxicoFil: Pineda, Carlos. Instituto Nacional de Rehabilitación; MéxicoFil: Portela Hernández, Margarita. Umae Hospital de Especialidades Centro Medico Nacional Siglo Xxi; MéxicoFil: Danza, Alvaro. Hospital Pasteur Montevideo; UruguayFil: Guibert Toledano, Marlene. Medical-surgical Research Center; CubaFil: Reyes, Gil Llerena. Medical-surgical Research Center; CubaFil: Acosta Colman, Maria Isabel. Hospital de Clínicas; ParaguayFil: Aquino, Alicia M.. Hospital de Clínicas; ParaguayFil: Mora Trujillo, Claudia S.. Hospital Nacional Edgardo Rebagliati Martins; PerúFil: Muñoz Louis, Roberto. Hospital Docente Padre Billini; República DominicanaFil: García Valladares, Ignacio. Centro de Estudios de Investigación Básica y Clínica; MéxicoFil: Orozco, María Celeste. Instituto de Rehabilitación Psicofísica; ArgentinaFil: Burgos, Paula I.. Pontificia Universidad Católica de Chile; ChileFil: Betancur, Graciela V.. Instituto de Rehabilitación Psicofísica; ArgentinaFil: Alarcón, Graciela S.. Universidad Peruana Cayetano Heredia; Perú. University of Alabama at Birmingahm; Estados Unido

Anais do V Encontro Brasileiro de Educomunicação: Educação midiática e políticas públicas

A presente coletânea, que chega ao público através de um suporte digital, tem como objetivo disponibilizar os papers, bem como os relatos de experiências educomunicativas apresentados durante o V ENCONTRO BRASILEIRO DE EDUCOMUNICAÇÃO, que teve como tema central: “Educação Midiática e Políticas Públicas”. O evento foi realizado em São Paulo, entre 19 e 21 de setembro de 2013, a partir de uma parceria entre o NCE/USP - Núcleo de Comunicação e Educação da USP, a Licenciatura em Educomunicação da ECA/USP, a ABPEducom – Associação Brasileira de Pesquisadores e Profissionais da Educomunicação e a FAPCOM – Faculdade Paulus de Tecnologia e Comunicação, que ofereceu seu campus, na Vila Mariana, para os atos do evento. Os presentes anais disponibilizam o texto de abertura, de autoria do coordenador geral do evento, denominado “Educação midiática e políticas públicas: vertentes históricas da emergência da Educomunicação na América Latina”. Na sequência, apresentam 61 papers sobre aspectos específicos da temática geral, resultantes de pesquisas na área, seguidos de 27 relatos de práticas educomunicativas, em nível nacional

The complete genome sequence of Chromobacterium violaceum reveals remarkable and exploitable bacterial adaptability

Chromobacterium violaceum is one of millions of species of free-living microorganisms that populate the soil and water in the extant areas of tropical biodiversity around the world. Its complete genome sequence reveals (i) extensive alternative pathways for energy generation, (ii) ≈500 ORFs for transport-related proteins, (iii) complex and extensive systems for stress adaptation and motility, and (iv) wide-spread utilization of quorum sensing for control of inducible systems, all of which underpin the versatility and adaptability of the organism. The genome also contains extensive but incomplete arrays of ORFs coding for proteins associated with mammalian pathogenicity, possibly involved in the occasional but often fatal cases of human C. violaceum infection. There is, in addition, a series of previously unknown but important enzymes and secondary metabolites including paraquat-inducible proteins, drug and heavy-metal-resistance proteins, multiple chitinases, and proteins for the detoxification of xenobiotics that may have biotechnological applications

Lower P1NP serum levels: a predictive marker of bone loss in premenopausal SLE patients

Objetivos: Determinar a incidência de perda de massa óssea em um ano em pacientes com lúpus na pré-menopausa e o valor preditor dos marcadores do metabolismo ósseo para essa complicação. Métodos: Sessenta e três pacientes foram avaliadas à entrada no estudo e após um ano de seguimento. Variações na densidade mineral óssea (DXA) acima da mínima variação significativa (MVS) foram consideradas significativas, como recomendado pela Sociedade Internacional de Densitometria Clínica (International Society for Clinical Densitometry). Os níveis séricos dos marcadores do metabolismo ósseo foram determinados no início do estudo: propeptídeo N-terminal do pro-colágeno tipo 1 (P1NP) e telopeptídeo C-terminal do colágeno tipo 1 (CTX) por eletroquimioluminescência; osteoprotegerina (OPG) e ligante do receptor ativador do fator nuclear kB (RANKL) por ELISA. Resultados: 36,5% dos pacientes apresentaram perda de massa óssea e 17,5% ganho de massa óssea na coluna lombar e/ou fêmur. Os pacientes foram divididos em três grupos: perda de massa óssea (P), massa óssea estável (E) e ganho de massa óssea (G). Pacientes com P e E tomaram doses cumulativa, média e máxima de glicocorticoide semelhantes durante o estudo, mas pacientes com G receberam doses menores (G vs. P e G vs. E, p < 0,05). Os níveis séricos basais de P1NP foram diferentes nos três grupos (P: 36,95 ± 23,37 vs. E: 54,63 ± 30,82 vs. G: 84,09 ± 43,85 ng/ml, p=0,001). Análises de múltiplas comparações demonstraram diferenças significativas nos níveis de P1NP entre P vs. E, p=0,031; P vs. G, p < 0,001 e E vs. G, p=0,039. Não houve diferença entre os grupos com relação aos níveis de CTX, OPG/RANKL, fatores de risco para osteoporose ou parâmetros relacionados à doença. Após análise multivariada, apenas níveis baixos de P1NP permaneceram como fator de risco independente para perda de massa óssea (p < 0,013). Conclusão: Este estudo fornece evidência original que níveis mais baixos de P1NP, o marcador de formação óssea mais específico, são preditores de perda de massa óssea em um ano em mulheres com lúpus na pré-menopausaObjective: To determine the one-year incidence of bone loss in premenopausal lupus patients and the value of bone markers as predictors of this complication. Methods: Sixty-three premenopausal SLE patients were evaluated at baseline and after one-year of follow-up. Bone mineral density changes (DXA) above the least significant change (LSC) were considered significant, as recommended by International Society for Clinical Densitometry. Serum levels of bone markers were determined at baseline: N-terminal propeptide of type 1 collagen (P1NP) and C-terminal telopeptide of type 1 collagen (CTX) by electrochemiluminescence; osteoprotegerin (OPG) and receptor activator of nuclear factor kB ligand (RANKL) by ELISA. Results: 36.5% of patients presented bone loss and 17.5% bone gain at lumbar spine and/or femur. Patients were divided in three groups: bone mass loss (BL), no bone mass change (NC) and bone mass gain (BG). Patients with BL e NC took similar cumulative, mean and maximum GC doses during the study, but patients with BG took lower doses (BG vs. BL and BG vs. NC, p < 0.05). Baseline P1NP levels were different in the three groups (BL: 36.95 ± 23.37 vs. NC: 54.63 ± 30.82 vs. BG: 84.09 ± 43.85 ng/ml, p=0.001). Further multiple comparison analysis demonstrated significant differences in P1NP between BL vs. NC, p=0.031; BL vs. BG, p < 0.001 and NC vs. BG, p=0.039. No difference was observed concerning the levels of CTX, OPG/RANKL, risk factors for osteoporosis or disease related parameters. After multivariate analysis only lower P1NP levels remained as an independent risk factor for bone loss (p < 0.013). Conclusion: This study provides original evidence that lower levels of P1NP, the most specific bone formation marker, are predictive of bone loss in the next year in premenopausal SLE patient

Características demográficas, clínicas, laboratoriais e radiológicas da febre reumática no Brasil: revisão sistemática Demographic, clinical, laboratorial, and radiological characteristics of rheumatic fever in Brazil: systematic review

A febre reumática (FR) se caracteriza por um processo inflamatório não supurativo que se instala após uma infecção pelo estreptococo beta-hemolítico do grupo A de Lancefield. Sua prevalência é maior nos países em desenvolvimento como o Brasil. Em nosso país, entretanto, dados epidemiológicos sistemáticos sobre a doença são incompletos e escassos. Estima-se uma prevalência de FR ao redor de 3% entre as crianças e os adolescentes brasileiros. Neste artigo, foi realizada uma revisão sistemática dos principais estudos brasileiros, utilizando como fonte de pesquisa as bases de dados do LILACS, Scielo e Medline, tendo como palavras-chave Febre Reumática e Rheumatic Fever. Foram selecionados 10 trabalhos epidemiológicos e a análise comparativa não demonstrou diferenças em relação a predominância de sexo, quadro clínico, laboratorial e radiológico dos pacientes nas diversas regiões do país.<br>Rheumatic fever (RF) is characterized by a non-suppurative inflammatory process that begins after a group A betahemolytic streptococci infection. Its prevalence is higher in developing countries, such as Brazil. However, in our country, systematic epidemiologic data on the disease are scarce and incomplete. Rheumatic fever has an estimated incidence of 3% among Brazilian children and adolescents. We undertook a systematic review of the main Brazilian studies using the LILACS, Scielo, and Medline databases searching for expressions like Febre Reumática and Rheumatic Fever. Ten epidemiological studies were selected and comparative analysis did not show a predominance of gender, clinical presentation, and laboratorial and radiological parameters in the different regions of the country

Juvenile onset systemic lupus erythematosus thyroid dysfunction: A subgroup with mild disease?

The aim of this study was to evaluate the frequency of thyroid dysfunction and thyroid antibodies in patients with juvenile onset Systemic Lupus Erythematosus (JOSLE) and its association with clinical and immunological features. Seventy-seven patients with JOSLE, 64 females, median age 19 years, were consecutively enrolled from March to December 2007. Clinical data related to thyroid dysfunction and lupus were obtained by chart review and patient interview. Serum levels of TSH, free T4, anti-thyroglobulin (TgAb), anti-thyroperoxidase (TPOAb), TRAb and lupus related autoantibodies were analyzed by standard techniques. Nine patients were diagnosed as hypothyroidism and 4 hyperthyroidism. 28% JOSLE patients had moderate/high titer of thyroid antibodies: 23% TgAb, 2.6% TPOAb and 3.9% TRAb. JOSLE patients with positive thyroid autoantibodies had higher frequency of anti-U1RNP antibodies than patients without these antibodies (40.9 vs. 14.5%, OR:0.25, CI:0.08-0.76, p = 0.017). Furthermore, renal/neurological/hematological involvement was less frequently observed in patients with hypothyroidism (55.6 vs. 87.5%, OR:0.18, CI:0.04-0.81, p = 0.035) and with thyroid antibodies (68.4 vs. 90.9%, OR:0.22, CI:0.06-0.82. p = 0.027) than in patients without these alterations. No association with PTPN22 polymorphism was found. In conclusion, JOSLE patients have high prevalence of subclinical hypothyroidism. The novel association of anti-thyroid antibodies with anti-U1RNP antibodies in JOSLE seems to identify a subgroup of patients with less life-threatening organ involvement. (C) 2009 Elsevier Ltd. All rights reserved